Novo Nordisk | NVO - Loan Capital


Novo Nordisk reported DKK18.61B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
ANI Pharmaceuticals USD 280.15M 5.84M Jun/2026
Aurora Cannabis CAD 18.13M 15.07M Mar/2026
Bausch Health Companies USD 19.88B 20M Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Canopy Growth CAD 217.12M 7.87M Mar/2026
Drreddys Laboratories INR 12.2B 12.07B Mar/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Nektar Therapeutics USD 60.27M 2.89M Mar/2026
Novartis USD 37.49B 42M Jun/2026
Novo Nordisk DKK 121.79B 2.62B Jun/2026
Novo Nordisk DKK 18.61B 100.56B Jun/2026
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.28B 337.7M Jun/2026
Phibro Animal Health USD 597.68M 5.92M Mar/2026
Prestige Brands USD 2.02B 1.01B Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Supernus Pharmaceuticals USD 400.38M 21.13M Mar/2022
Zoetis USD 9.05B 3M Jun/2026